Role of systemic chemotherapy in urothelial urinary bladder cancer

Shilpa Gupta, Amit Mahipal

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Radical cystectomy is the standard of care for patients with localized muscle-invasive bladder cancer; however, 50% of patients still relapse in distant sites following surgery. A systemic approach is needed to improve outcomes in bladder cancer in the metastatic and perioperative settings. Methods: We reviewed the literature for use of systemic chemotherapy in bladder cancer and its role in metastatic, neoadjuvant, and adjuvant settings, including patients with comorbidities and renal dysfunction. Current controversies on the role of chemotherapy in neoadjuvant and adjuvant settings as well as the role of novel agents are discussed. Results: First-line cisplatin-based polychemotherapy improves survival in the metastatic setting and is the standard of care. Approved regimens for subsequent-line therapy do not exist. Chemotherapy has a modest benefit in the neoadjuvant setting, but evidence is insufficient to justify its role in the adjuvant setting despite a possible benefit. Carboplatin cannot be substituted for cisplatin in fit patients, and the addition of taxane to a standard regimen cannot be recommended. Conclusions: Systemic chemotherapy plays a central role in the management of invasive bladder cancer in the metastatic and neoadjuvant settings, but its role in the adjuvant setting remains undefined. Neoadjuvant chemotherapy is underutilized and should be routinely used. Pathological downstaging strongly correlates with improved outcomes and may serve as a surrogate end point for survival. An urgent need exists for the development of novel therapeutic agents to improve outcomes.

Original languageEnglish (US)
Pages (from-to)200-210
Number of pages11
JournalCancer Control
Volume20
Issue number3
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Drug Therapy
Standard of Care
Cisplatin
Survival
Cystectomy
Carboplatin
Combination Drug Therapy
Comorbidity
Biomarkers
Kidney
Recurrence
Muscles
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Role of systemic chemotherapy in urothelial urinary bladder cancer. / Gupta, Shilpa; Mahipal, Amit.

In: Cancer Control, Vol. 20, No. 3, 01.01.2013, p. 200-210.

Research output: Contribution to journalArticle

@article{9e9dec2fe4a04e2ba950e8bf2327df1f,
title = "Role of systemic chemotherapy in urothelial urinary bladder cancer",
abstract = "Background: Radical cystectomy is the standard of care for patients with localized muscle-invasive bladder cancer; however, 50{\%} of patients still relapse in distant sites following surgery. A systemic approach is needed to improve outcomes in bladder cancer in the metastatic and perioperative settings. Methods: We reviewed the literature for use of systemic chemotherapy in bladder cancer and its role in metastatic, neoadjuvant, and adjuvant settings, including patients with comorbidities and renal dysfunction. Current controversies on the role of chemotherapy in neoadjuvant and adjuvant settings as well as the role of novel agents are discussed. Results: First-line cisplatin-based polychemotherapy improves survival in the metastatic setting and is the standard of care. Approved regimens for subsequent-line therapy do not exist. Chemotherapy has a modest benefit in the neoadjuvant setting, but evidence is insufficient to justify its role in the adjuvant setting despite a possible benefit. Carboplatin cannot be substituted for cisplatin in fit patients, and the addition of taxane to a standard regimen cannot be recommended. Conclusions: Systemic chemotherapy plays a central role in the management of invasive bladder cancer in the metastatic and neoadjuvant settings, but its role in the adjuvant setting remains undefined. Neoadjuvant chemotherapy is underutilized and should be routinely used. Pathological downstaging strongly correlates with improved outcomes and may serve as a surrogate end point for survival. An urgent need exists for the development of novel therapeutic agents to improve outcomes.",
author = "Shilpa Gupta and Amit Mahipal",
year = "2013",
month = "1",
day = "1",
doi = "10.1177/107327481302000308",
language = "English (US)",
volume = "20",
pages = "200--210",
journal = "Cancer Control",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "3",

}

TY - JOUR

T1 - Role of systemic chemotherapy in urothelial urinary bladder cancer

AU - Gupta, Shilpa

AU - Mahipal, Amit

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background: Radical cystectomy is the standard of care for patients with localized muscle-invasive bladder cancer; however, 50% of patients still relapse in distant sites following surgery. A systemic approach is needed to improve outcomes in bladder cancer in the metastatic and perioperative settings. Methods: We reviewed the literature for use of systemic chemotherapy in bladder cancer and its role in metastatic, neoadjuvant, and adjuvant settings, including patients with comorbidities and renal dysfunction. Current controversies on the role of chemotherapy in neoadjuvant and adjuvant settings as well as the role of novel agents are discussed. Results: First-line cisplatin-based polychemotherapy improves survival in the metastatic setting and is the standard of care. Approved regimens for subsequent-line therapy do not exist. Chemotherapy has a modest benefit in the neoadjuvant setting, but evidence is insufficient to justify its role in the adjuvant setting despite a possible benefit. Carboplatin cannot be substituted for cisplatin in fit patients, and the addition of taxane to a standard regimen cannot be recommended. Conclusions: Systemic chemotherapy plays a central role in the management of invasive bladder cancer in the metastatic and neoadjuvant settings, but its role in the adjuvant setting remains undefined. Neoadjuvant chemotherapy is underutilized and should be routinely used. Pathological downstaging strongly correlates with improved outcomes and may serve as a surrogate end point for survival. An urgent need exists for the development of novel therapeutic agents to improve outcomes.

AB - Background: Radical cystectomy is the standard of care for patients with localized muscle-invasive bladder cancer; however, 50% of patients still relapse in distant sites following surgery. A systemic approach is needed to improve outcomes in bladder cancer in the metastatic and perioperative settings. Methods: We reviewed the literature for use of systemic chemotherapy in bladder cancer and its role in metastatic, neoadjuvant, and adjuvant settings, including patients with comorbidities and renal dysfunction. Current controversies on the role of chemotherapy in neoadjuvant and adjuvant settings as well as the role of novel agents are discussed. Results: First-line cisplatin-based polychemotherapy improves survival in the metastatic setting and is the standard of care. Approved regimens for subsequent-line therapy do not exist. Chemotherapy has a modest benefit in the neoadjuvant setting, but evidence is insufficient to justify its role in the adjuvant setting despite a possible benefit. Carboplatin cannot be substituted for cisplatin in fit patients, and the addition of taxane to a standard regimen cannot be recommended. Conclusions: Systemic chemotherapy plays a central role in the management of invasive bladder cancer in the metastatic and neoadjuvant settings, but its role in the adjuvant setting remains undefined. Neoadjuvant chemotherapy is underutilized and should be routinely used. Pathological downstaging strongly correlates with improved outcomes and may serve as a surrogate end point for survival. An urgent need exists for the development of novel therapeutic agents to improve outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84879513938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879513938&partnerID=8YFLogxK

U2 - 10.1177/107327481302000308

DO - 10.1177/107327481302000308

M3 - Article

C2 - 23811704

AN - SCOPUS:84879513938

VL - 20

SP - 200

EP - 210

JO - Cancer Control

JF - Cancer Control

SN - 1073-2748

IS - 3

ER -